Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 155,834	[1]	$ 27,361	[1]
Marketable securities	25,004	[1]	0	[1]
Accounts receivable, net	21,372	[1]	21,162	[1]
Inventory, net	19,516	[1]	22,261	[1]
Prepaid expenses and other current assets	19,551	[1]	7,873	[1]
Total current assets	241,277	[1]	78,657	[1]
Property, plant, equipment, and investment properties, net	17,027	[1]	16,526	[1]
Intangible assets, net	77,333	[1]	84,238	[1]
In-process research and development	793,312	[1]	11,546	[1]
Goodwill	222,340	[1]	80,450	[1]
Investments, net	24,690	[1]	15,636	[1]
Other assets	7,003	[1]	2,777	[1]
Total assets	1,382,982	[1]	289,830	[1]
Current liabilities:
Accounts payable	13,631	[1]	10,200	[1]
Accrued expenses	43,269	[1]	24,656	[1]
Current portion of lines of credit and notes payable	14,477	[1]	17,526	[1]
Total current liabilities	71,377	[1]	52,382	[1]
3.00% convertible senior notes, net of discount and estimated fair value of embedded derivatives	208,917	[1]	0	[1]
Other long-term liabilities, principally contingent consideration and deferred tax liabilities	234,762	[1]	34,168	[1]
Total long-term liabilities	443,679	[1]	34,168	[1]
Total liabilities	515,056	[1]	86,550	[1]
Commitments and contingencies:		[1]		[1]
Series D Preferred Stock - $0.01 par value, 2,000,000 shares authorized; no shares issued or outstanding at September 30, 2013 and 1,129,032 shares issued and outstanding (liquidation value of $30,595) at December 31, 2012	0	[1]	24,386	[1]
Equity:
Common Stock - $0.01 par value, 500,000,000 shares authorized; 408,903,912 and 305,560,763 shares issued at September 30, 2013 and December 31, 2012, respectively	4,089	[1]	3,056	[1]
Treasury Stock - 2,293,056 shares at both September 30, 2013 and December 31, 2012	(7,457)	[1]	(7,457)	[1]
Additional paid-in capital	1,357,235	[1]	565,201	[1]
Accumulated other comprehensive income	3,237	[1]	7,356	[1]
Accumulated deficit	(486,377)	[1]	(388,770)	[1]
Total shareholders’ equity	870,727	[1]	179,386	[1]
Noncontrolling interests	(2,801)	[1]	(492)	[1]
Total equity	867,926	[1]	178,894	[1]
Total liabilities, Series D Preferred Stock, and equity	1,382,982	[1]	289,830	[1]
Series A Preferred Stock
Equity:
Preferred Stock	0	[1]	0	[1]
Series C Preferred Stock
Equity:
Preferred Stock	$ 0	[1]	$ 0	[1]

[1] As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.